CAMBRIDGE, Mass.--(BUSINESS WIRE)--Generation Bio, a company developing the first genetic medicines that can be re-dosed and titrated to effect for a lifetime of benefit, today announced that Tom Graney will be appointed chief financial officer (CFO). Tom joins the Generation Bio team from Vertex Pharmaceuticals where he served as CFO.
“We are delighted to welcome Tom to the Generation Bio community,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “Tom brings tremendous breadth to all aspects of the role including financial strategy, operations, and a strong commercial foundation.”
Graney brings 25 years of experience in the biopharmaceutical industry to Generation Bio. At Vertex, Graney led the development and execution of financial strategy and operations, and was responsible for the finance, accounting and internal audit functions. At Ironwood, he was responsible for finance, accounting, corporate strategy, corporate development, quality, supply chain, IT, corporate communications and investor relations. Before Ironwood, he spent 20 years with Johnson & Johnson, serving in various roles in the U.S. and abroad, most recently as worldwide vice president of finance and CFO for Ethicon Surgical Care, a leading medical device company. Graney serves on the board of directors of AC Immune SA, a clinical stage Swiss biopharmaceutical company focused on neurodegenerative diseases. A Chartered Financial Analyst charterholder, Tom holds a Bachelor of Science degree in accounting from the University of Delaware and a Master of Business Administration in marketing, finance and international business from the Leonard N. Stern School of Business at New York University.
“Generation Bio is pioneering a unique and powerful platform with the potential to create genetic medicines capable of treating patients for a lifetime,” said Graney. “I’m very excited to join the team and to add my energies to this mission.”
About Generation Bio
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease. The company’s therapies are based on its proprietary ceDNA technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime. Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.generationbio.com or follow @lifetimegenetx.